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Summary
Galactokinase deficiency is an inborn error in the first
step of galactose metabolism. Its major clinical mani-
festation is the development of cataracts in the first
weeks of life. It has also been suggested that carriers of
the deficiency are predisposed to presenile cataracts de-
veloping at age 20–50 years. Newborn screening data
suggest that the gene frequency is very low worldwide
but is higher among the Roma in Europe. Since the clon-
ing of the galactokinase gene (GK1) in 1995, only two
disease-causing mutations, both confined to single fam-
ilies, have been identified. Here we present the results
of a study of six affected Romani families fromBulgaria,
where index patients with galactokinase deficiency have
been detected by the mass screening. Genetic linkage
mapping placed the disease locus on 17q, and haplotype
analysis revealed a small conserved region of homozy-
gosity. Using radiation hybrid mapping, we have shown
that GK1 is located in this region. The founder Romani
mutation identified in this study is a single nucleotide
substitution in GK1 resulting in the replacement of the
conserved proline residue at amino acid position 28 with
threonine (P28T). The P28T carrier rate in this endog-
amous population is ∼5%, suggesting that the mutation
may be an important cause of early childhood blindness
in countries with a sizeable Roma minority.
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Introduction
Galactokinase (EC 2.7.1.6) catalyzes the first step of
galactose phosphorylation in the Leloir pathway of in-
termediate metabolism. Galactokinase deficiency (MIM
230200), one of the three inborn errors of metabolism
that lead to hypergalactosemia, was first described by
Gitzelmann (1965, 1967). The disorder is inherited as
an autosomal recessive trait. Unlike classic galactosemia,
which is caused by deficiency of galactose-1-phosphate
uridyltransferase (MIM 230400), galactokinase defi-
ciency does not present with severe manifestations in
early infancy. Its major clinical symptom is the devel-
opment of cataracts during the first weeks or months of
life, as a result of the accumulation, in the lens, of gal-
actitol, a product of an alternative route of galactose
utilization. The development of early cataracts in ho-
mozygous affected infants is fully preventable through
early diagnosis and treatment with a galactose-restricted
diet. Some studies have suggested that, depending on
milk consumption later in life, heterozygous carriers of
galactokinase deficiency may be prone to presenile cat-
aracts at 20–50 years of age (Stambolian et al. 1986).
Galactokinase deficiency is generally considered to be
rare, compared to classic galactosemia; however, the es-
timates of gene frequency vary widely, and an east-to-
west gradient appears to be present across Europe (table
1). Observations coming from independent sources sug-
gest interpopulation variation and point to a high in-
cidence of the disorder among the Roma. Galactokinase
deficiency has been reported in Roma patients fromSwit-
zerland, Austria, and Italy (Gitzelmann 1967; Thalham-
mer et al. 1968; Bolgiani et al. 1984). All patients de-
tected by the neonatal screening in Bulgaria (Kalaydjieva
and Kremensky 1992) and 10 of the 21 galactokinase-
deficient subjects studied by Gitzelmann (1987) are of
Romani descent. Our previous studies of genetically iso-
lated Romani populations (Kalaydjieva et al. 1996; An-
gelicheva et al. 1999) lead us to predict that galactoki-
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Table 1
Newborn Screening Data on the Birth Incidence of Galactokinase Deficiency
Source Tested Detected Incidence Reference
“World” (Europe, USA, Asia) (1980) 6,000,000 6 1:1,000,000 Levy (1980)
Switzerland (1997) 2,200,000 1 1:2,200,000 Gitzelmann and Steinmann, unpublished data
Germany (1980) 1,100,000 7 1:157,000 Gitzelmann and Hansen (1980)
Austria (1980) 920,000 6 1:153,000 Gitzelmann and Hansen (1980)
Bulgaria (1988) 726,678 14 1:52,000 Kalaydjieva and Kremensky, unpublished data
nase deficiency in the Roma is genetically homogeneous
and is caused by a private founder mutation.
In view of its low efficiency in detecting classic galac-
tosemia, many mass-screening programs have discontin-
ued testing for blood galactose. Instead, such testing has
become part of the battery of selective-screening tests
performed under clinical indications. The lack of early
dramatic signs of a metabolic disorder in galactokinase
deficiency implies that affected children will not attract
medical attention and that their disorder will only be
diagnosed after the development of lens opacities and
blindness. Therefore, the identification of the founder
galactokinase mutation would make possible the incor-
poration of a simple diagnostic test in themass-screening
programs of countries with a sizeable Roma population
and, thus, would allow the early diagnosis and dietary
treatment of a common cause of disability.
Since the cloning of the galactokinase gene GK1
(Stambolian et al. 1995), only two disease-causing mu-
tations, V32M and Q80X, have been described (Stam-
bolian et al. 1995), and conclusive data on the role of
the gene in galactokinase deficiency are still missing.
Here we present the results of refined genetic and phys-
ical mapping showing that GK1 is the gene responsible
for galactokinase deficiency in the Roma. Sequencing
analysis of the gene has revealed one single-nucleotide
variation that results in an amino-acid substitution in
the galactokinase protein and that is likely to be the
founder Romani mutation. In view of the ethnic distri-
bution of galactokinase deficiency, this may also be the
major defect leading to this disorder worldwide.
Subjects and Methods
Patients and Families with Galactokinase Deficiency
The study included eight galactokinase-deficient Ro-
mani children from Bulgaria. The clinical and biochem-
ical information on the patients is shown in table 2. Six
were identified as being hypergalactosemic by the neo-
natal screening program and subsequently were shown,
by means of enzyme analysis, to have galactokinase de-
ficiency. In addition, two affected relatives (4-7 and 4-
1), born either before the initiation or after the discon-
tinuation of the hypergalactosemia screening, were iden-
tified in the family shown in fig. 1. In the same kindred,
individual M.K.N. (4-5 in fig. 1), who is the mother of
an affected male, reported a history of juvenile cataracts,
for which she had undergone surgery. The galactokinase
activity of this individual, determined as part of the pre-
sent study, was 0.23 mmol/h/ml RBC. Enzyme activity
has also been determined in individuals 4-10 (themother
of patient 4-11) and 4-13 (the maternal grandmother of
patient 4-3). It was reduced in individual 4-10 (0.26
mmol/h/ml RBC) and was within the normal range in
individual 4-13 (0.83 mmol/hr/ml RBC).
The patients belong to six unrelated families that orig-
inate from three different Romani groups: Thracian Tin-
kers, Kalderas, and Rudari. Despite their current social
divergence, these groups have a common history of mi-
grations in the northern part of the Balkan peninsula
and a strong linguistic influence from Rumanian. The
overall number of family members included in the study
is 41.
The study complies with the ethical guidelines of the
institutions involved. Informed consent was obtained
from all adult subjects included in the study and from
the parents of the children investigated.
Population Screening
The population frequency of the mutation was ana-
lyzed in a sample of 194 anonymized adult controls with
no family history of galactokinase deficiency: 130 from
the Kalderas and Rudari Romani groups and 64
Bulgarians.
Linkage Analysis
The genetic linkage study of the affected families
started with the long arm of chromosome 17. This choice
was based on the fact that the candidate gene, GK1,
where mutations had been identified previously in two
patients with galactokinase deficiency (Stambolian et al.
1995), had been roughly mapped, by use of FISH, to
17q24.
DNA was extracted from venous blood as described
by Miller (1988). The six families were genotyped for
20 microsatellite markers spanning ∼47 cM. Microsa-
tellites D17S808, D17S949, D17S802, D17S794, and
D17S929 from the ABI mapping panel were used in the
initial scan, which aimed at the exclusion of linkage to
this region or roughly positioning the gene. These mark-
ers were PCR amplified using the ABI fluorescently la-
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Table 2
Clinical Information on the Galactokinase-Deficient Patients Detected by the Newborn Screening
Patient
Year of
Birth
Blood Galactose
Screening Value
(mg/dl)
Initiation of
Treatment
Jaundice,
Vomiting,
Infection
aSerum
GOT
(IU/L)
aSerum
GPT
(IU/L)
bGalactokinase
(mmol/h/ml RBC)
cGal-1-P
Uridyltransferase
(mmol/h/g Hb) Cataracts
D.P.H 1981 110 45 d No 20 8 .06 26.3 No
S.M.I 1983 115 30 d No 16 6 .02 35.6 No
S.H.G 1984 90 36 d No 11 2 .15 43.3 No
T.V.I. 1984 125 3.5 mo No 15 9 0 33.4 Yes
P.P.V. 1985 99 20 d No 12 12 .11 36.9 No
I.L.S. 1986 143 34 d No 10 8 0 29.7 No
a Normal range for SGOT and SGP IU/L.T ! 18
b Normal range for galactokinase: 0.69–2.57 (2 wk–9 mo); 0.42–0.99 (19 mo).
c Normal range for galactose-1-phosphate uridyltransferase: 18.9–37.9.
beled primers, in a 5-ml final volume containing 5–10
ng genomic DNA, 0.2 mM each primer, 0.25 mM each
dNTP, 1.5 mM MgCl2, 1# PCR buffer (PE Biosystems
N808-0010), and 0.2 U of AmpliTaqTM DNA polymer-
ase (PE Biosystems N808-0101). The PCR products
were length separated on an ABI 373XLDNA sequencer
in a 24-cm well-to-read 6% 19:1 acrylamide/bisacrylam-
ide gel at 1400 V for 7 h. Polymorphic alleles were
analyzed using ABI GenotyperTM (Version 2) software.
Additional markers used subsequently to create a
denser map of the relevant interval were selected from
the genetic maps in the public-domain databases and
PCR amplified using the primer sequences indicated in
the Genome Database. Radioactive labeling was done
through incorporation of a[32]P-dCTP in the product
during PCR amplification. The PCR products were elec-
trophoresed on 6% 19:1 acrylamide/bisacrylamide gels
at 1400 V for 2–3 h. The gels were dried and autora-
diographed for 12–48 h. Alleles were scored manually.
Linkage analysis was conducted under an autosomal
recessive model with 100% penetrance with two differ-
ent gene frequencies (0.01 and 0.05). Two-point analysis
was performed using FASTLINK (Lathrop and Lalouel
1984) and multipoint analysis was done with GENE-
HUNTER (Kruglyak et al. 1995). In the linkage analysis,
the affection status of M.K.N. (individual 4-5 in the
pedigree in fig. 1) was considered unknown. Haplotypes
were constructed manually and were inspected for over-
lapping regions of homozygosity and for historical
recombinations.
Radiation-Hybrid Mapping
The physical position of the GK1 gene, relative to
the region of linkage, was established through radia-
tion-hybrid mapping using the Stanford TNG panel. The
analyses included a 293-bp sequence representing the
GK1 gene (nucleotide positions 2071–2373, Gen-
Bank accession number L76927) and microsatellites
D17S1839, D17S1603, and D17S801. PCR amplifica-
tion of the microsatellite markers was performed using
the primer sequences provided in the Genome Database.
The primers used for the GK1 fragment were 5′-CCTA-
GAAACAGTTGCTAGGC-3′ and 5′-ATAGTAGAAGC-
TGGGACCAC-3′; cycling was in a touch-down regime
with denaturing at 94C for 30 s, elongation at 72C
for 30 s, and annealing from 63C to 55C, decreasing
at 0.5o increments for the 16 initial cycles, followed by
20 cycles at 55C for 30 s.
The results were analyzed using the software package
“RH2PT,” version 3.0 (September 1996), written by
Elizabeth Hauser and Michael Boehnke.
Sequence Analysis of the GK1 Gene
The analysis included the entire coding sequence of
GK1, along with 100–150 bp of the flanking introns
and the 5′ UTR. Direct sequencing of both strands was
performed after PCR amplification of genomic DNA
from galactokinase-deficient individuals and control
samples from a different population. The primer se-
quences are shown in table 3. PCR reactions were done
with 30 ng total genomic DNA, 7 pmol each primer, 0.2
mM each dNTP, 1.5 mM MgCl2, 5%–15% DMSO, 1
# PCR buffer (PE Biosystems N808-0010), and 0.5 U
AmpliTaq (PE Biosystems N808-0101) in a final volume
of 25 ml. The PCR products were purified using
QiagenTM columns, according to the instructions of the
manufacturer.
Sequencing reactions were performed using the ABI
PrismTM Dye Terminator cycle sequencing kit and were
run on an ABI 373 XL DNA sequencer. Alignment to
the published genomic or cDNA sequence of GK1 was
done using Sequence NavigatorTM (PE Biosystems).
Restriction Assay for the Detection of the Mutation
A 272-bp DNA fragment spanning the region between
nucleotides 478 and 749 in the GK1 sequence (GenBank
accession number L76927) was amplified from genomic
DNA by use of primers 5′-CGTCATGGCTGCTTT-
GAGAC-3′ and 5′-TAGAGGGCGCCCTTCTTGAG-3′.
The PCR mix contained 30 ng total genomic DNA, 7
pmol each primer, 0.2 mM of each dNTP, 1.5 mM
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Figure 1 Romani family with galactokinase deficiency. The proband P.P.V. (individual 4-3) was detected by the neonatal screening program,
whereas the two affected cousins, K.N.S (individual 4-7) and K.P.T. (individual 4-11), were born before the initiation of the screening and after
the discontinuation of its hypergalactosemia component, respectively. Individual 4-5 reported a history of infantile cataracts and was found to
be homozygous for the P28T mutation; her erythrocyte galactokinase activity was in the intermediate range.
MgCl2, 5% DMSO, 1 # PCR buffer (Perkin Elmer
N808-0010), and 0.5 U AmpliTaq (PE Biosystems
N808-0101) in a 20-ml total volume. PCR cycling was
performed at initial denaturing at 94oC for 5 min; 15
cycles at a touch-down regime of denaturing at 94oC for
20 s, annealing from 60oC to 55oC (0.5oC increments)
for 60 s, and extension at 72oC for 30 s; 15 cycles of
94oC for 20 s, 55oC for 60 s, and 72oC for 30 s; and a
final extension step at 72oC for 7 min. The PCR product
was ethanol precipitated, resuspended in 20 ml of dH2O,
and then cut with Ava I. The restriction fragments were
separated by electrophoresis on a 2.5% agarose gel and
were visualized by ethidium-bromide staining.
Secondary Structure–Prediction Analysis of the Wild-
Type and Mutant Galactokinase Proteins
In order to relate P28T and a known mutation, V32M
(Stambolian et al. 1995), to conformational changes of
functional significance, a secondary structure–prediction
analysis was performed for the complete amino acid se-
quence (392 amino acids) of the wild-type and mutant
proteins. The prediction analysis was performed by
means of the PHDsec algorithm (Rost et al. 1994) on
an 8-processor SGI Origin 2000 platform (dodo.cpmc
.columbia.edu).
Results
Linkage of the Disease Gene to 17q24
Linkage analysis (table 4) excluded most of the long
arm of chromosome 17. Positive LOD scores were ob-
tained for the region 17q24-q25. The maximum two-
point LOD score of 4.382 was obtained for D17S801
at recombination fraction (v) 0. The results were not
substantially affected by changing the gene frequency.
Multipoint results peaked in the interval D17S1839/
D17S1603/ D17S801.
Haplotype analysis revealed a conserved haplotype,
spanning a distance of ∼6 cM, that was found in most
disease chromosomes (fig. 2). The highly conserved re-
gion of homozygosity shared by all mutant chromo-
somes was defined by markers D17S1839 and
D17S1603, which, according to the Genethon map, are
located !1 cM apart. Allele 2 of marker D17S1839 is
in strong linkage disequilibrium with the disease,
whereas allele 1 of D17S1603, which is found in all
disease chromosomes, is also the predominant normal
allele—hence the low LOD score and TDT P value ob-
tained for this marker (fig. 2).
These results point to 17q24 as the region containing
the disease gene in the Romani families. The data co-
incide with the cytogenetic location of the GK1 gene, as
determined by FISH (Stambolian et al. 1995). The con-
served polymorphic haplotypes found in disease chro-
mosomes from unrelated families suggest that affected
individuals are homozygous for the same founder mu-
tation, which, on the basis of linkage disequilibrium
analysis, should be located in close proximity to marker
D17S1839.
Physical Mapping of GK1 Relative to the Linkage
Region
Radiation-hybrid mapping was used to determine the
physical position of GK1 relative to D17S1839 and
D17S1603, the two markers defining the conserved ho-
mozygosity region, and to D17S801, where the highest
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Table 3
PCR Primer Sequences Used in the Sequence Analysis of the GK1 Gene
Sequence
Name Primer Sequence Nucleotide Positions
5′ UTR (F) 5′-CAGCTCCATTGCTCTGG-3′ 74–93
5′ UTR (R) 5′-CAGCAGCTGGATTCCCACG-3′ 299–317
1 (F) 5′-CCCGAGCATCCCGCGCCGAC-3′ 419–438
1 (R) 5′-GACAGGCTGTTCCCCACGT-3′ 800–818
2 (F) 5′-ACTGTGGAGGCATCAGAACC-3′ 1436–1455
2 (R) 5′-CACAGAGCCCATTCATTTGTCTGA-3′ 1781–1805
3 (F) 5′-CCTAGAAACAGTTGCTAGGC-3′ 2071–2090
3 (R) 5′-GTGGTCCCAGCTTCTACTAT-3′ 2354–2373
4 (F) 5′-AGTGTCATTGAAGCCACTGC-3′ 2408–2427
4 (R) 5′-CAAGCACACGCTTGGCCTCGT-3′ 2686–2706
5 (F) 5′-AGCAGCTCCTGGGTGGAGTGT-3′ 2647–2667
5 (R) 5′-CTCAGTGTGGCCTTGACCT-3′ 2971–2990
6 (F) 5′-ATCACCGCCTGCTGGTCCTC-3′ 6945–6964
7 (F) 5′-CTCATGGTGGAGAGCCACCG-3′ 7146–7165
7 (R) 5′-CTCAAGCAGCCGATGGAGCC-3′ 7530–7549
8 (F) 5′-ACGCCATGCGGCACATCCAG-3′ 7394–7413
8 (R) 5′-CTCTGTGCCCGGTGCCATCTT-3′ 7624–7644
two-point LOD score had been obtained. The high res-
olution of the TNG panel allowed the separation of these
loci and the positioning of GK1, despite the close prox-
imity between galactokinase and thymidine kinase. Ev-
idence of linkage was obtained between GK1 and
D17S1839, with a LOD score of 12.86 and breakage
probability (PBR) of .1139. For the other two markers,
D17S1603 and D17S801, the LOD scores obtained
were, respectively, 1.45 and 0, and the PBR values were
.699 and 1. These findings indicate that GK1 is !300
kb from marker D17S1839.
The GK1 Mutation in Galactokinase-Deficient Patients
The analysis of the entire coding sequence of GK1,
the flanking intronic sequences, and the 5′ UTR has iden-
tified one single mutation. This is a CrA transversion
in exon 1 that occurs either at nucleotide position 563,
according to the GenBank numbering (accession number
L76927), or at nucleotide position 82, according to the
Bergsma et al. (1996) nucleotide numbering. The nucle-
otide substitution gives rise to a missense muta-
tion—namely, the replacement of proline by threonine
at amino acid position 28 (P28T). P28T was present in
the homozygous state in affected individuals. The con-
trol subjects displayed the published wild-type sequence.
No other differences were found between the galacto-
kinase-deficient individuals, the controls, and the pub-
lished GK1 sequence, as regards the remaining part of
the coding region, the intronic sequences flanking the
exons, and the 5′ UTR.
The P28T mutation abolishes an Ava I–restriction site
and thus can be detected through PCR-based restriction
analysis. The Ava I–restriction assay was performed on
all family members, including grandparents and unaf-
fected siblings. The restriction pattern coincided 100%
with the carrier status of unaffected family members pre-
dicted on the basis of haplotype analysis. It also coin-
cided with the measured levels of galactokinase activity
in individuals 4-10 (carrier, decreased activity) and 4-13
(noncarrier, normal activity). Individual 4-5, who is the
mother of an affected patient and who developed cat-
aracts in early childhood, was found to be homozygous
for both the disease haplotype and the mutation.
Modeling of the Secondary Structure of the Mutant
P28T and V32M Proteins
Secondary-structure prediction analysis was per-
formed in comparison with the wild-type protein and
with the protein containing the known amino acid sub-
stitution V32M (Stambolian et al. 1995). The results
indicate that both mutations induce topology changes
in the loop–beta turn motif formed by the wild-type
sequence AEPELAVSA, immediately preceding the gal-
actokinase signature domain GRVNLIGEHTDY (fig. 3).
These differences are clearly visible on the detailed pre-
diction maps (SUBsec). V32M causes an extension of
the loop with one amino acid (G25) and disturbs the
succeeding beta turn (LAV). P28T acts in a similar way,
by extending and shifting the loop to F24 and by dis-
turbing the succeeding beta turn.
Population Screening for P28T
We have used the Ava I assay to estimate the frequency
of the mutation among a total of 194 unrelated adult
control individuals. In the control group of 130 indi-
viduals originating from the Kalderas and Rudari Ro-
mani groups, we detected six heterozygotes for P28T.
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Table 4
Two-Point LOD Scores for Markers on Chromosome 17q
MARKERS
LOD SCORE AT v =
0 .05 .1 .15 .2 .25 .3 .35 .4
D17S808 1.27 .38 .14 .04 .006 .006 .009 .009 .008
D17S807 4.44 .59 .01 .22 .30 .30 .25 .18 .10
D17S840 1.09 .16 .25 .21 .17 .13 .09 .007 0
D17S949  1.50 .7 .33 .15 .06 .01 .004 .009
D17S1797 2.43 2.08 1.73 1.39 1.06 .76 .50 .29 .04
D17S1862 1.7 .05 .32 .39 .39 .35 .30 .23 .16
D17S1352 3.02 2.69 2.28 1.86 1.44 1.06 .73 .45 .24
D17S1807 3.22 2.69 2.18 1.72 1.30 .95 .65 .41 .23
D17S1602 2.32 2.15 1.86 1.52 1.18 .86 .59 .37 .21
D17S1864 2.87 2.51 2.08 1.63 1.22 .86 .56 .34 .18
D17S929 3.29 2.94 2.50 2.05 1.61 1.19 .83 .52 .28
D17S1839 3.02 2.53 2.06 1.62 1.23 .90 .63 .41 .24
D17S1603 1.34 1.16 .97 .79 .61 .45 .32 .20 .11
D17S801 4.38 3.70 3.04 2.41 1.83 1.32 .88 .54 .27
D17S1817 3.62 3.05 2.52 2.00 1.54 1.13 .78 .49 .28
D17S802 .59 1.47 1.40 1.22 1.01 .79 .59 .41 .25
D17S937 .28 .63 .58 .47 .34 .23 .14 .07 .03
D17S1847  .3 .1 0 .04 .05 .04 .03 .02
D17S1806 1.70 1.19 .85 .59 .40 .26 .17 .098 .04
D17S784 1.48 .85 .55 .38 .27 .197 .137 .085 .039
D17S928 .96 .70 .49 .31 .18 .097 .046 .018 .005
No carriers were identified among the 64 Bulgarian
controls.
These results suggest that, in the Romani groups
screened, the carrier rate for P28T is ∼5%. By contrast,
the mutation appears to be absent in control individuals
from the non-Romani Bulgarian population.
Discussion
The galactokinase-deficient individuals included in
this study have been diagnosed, on days 4–5 after birth,
as having hypergalactosemia. None of the patients have
manifested clinical or biochemical symptoms suggestive
of classic galactosemia; however, three of the eight af-
fected individuals have developed cataracts. T.V.I. was
diagnosed by the screening, but treatment was delayed;
K.N.S. and K.P.T. were born before the initiation and
after the discontinuation, respectively, of the hyperga-
lactosemia screening. Galactokinase activity in these pa-
tients, which was measured during the first 2 mo of life,
ranged from 0 to .15 mmol/h/ml RBC, with a mean of
0.056, whereas the normal range for the same age group
is .69–2.57, with a mean value of 1.29 mmol/h/ml RBC.
Diagnostic measurements of galactokinase activity are
routinely performed in red blood cells, where the activity
of the enzyme is ∼50 times lower than that in liver (Shin-
Buehring et al. 1977). The assay relies on the use of
radioactively labeled substrate, and minor fluctuations
in the measured activity can be caused by the quality of
substrate purification as well as by reticulocyte counts.
The test is, therefore, highly reliable for the diagnosis of
galactokinase deficiency but is not sensitive enough to
discriminate between complete deficiency and very low
residual activity. Our biochemical and clinical obser-
vations are sufficient to conclude that the Romani gal-
actokinase mutation leads to a drastic reduction in ne-
onatal enzyme activity (with the mean value in affected
individuals constituting !5% of the mean in controls of
the same age) and that, in untreated homozygotes, the
reduced activity results in the development of cataracts
during the first 3 mo of life.
The size and structure of the families included in this
study, and the genetic homogeneity and recent founder
effect observed in endogamous Romani groups, have
allowed us to map the galactokinase-deficiency locus to
17q24, the same region that has been shown, by means
of FISH, to contain GK1 (Stambolian et al. 1995). Ra-
diation-hybrid mapping of the GK1 sequence, relative
to the conserved region of homozygosity, confirmed that
GK1 is located within this region. Both sets of results
pointed to GK1 as the gene responsible for galactokinase
deficiency in Bulgarian Gypsies. Haplotype analysis has
indicated that, like other single-gene disorders in this
population (Kalaydjieva et al. 1996; Angelicheva et al.
1999), galactokinase deficiency is caused by a single
founder mutation shared by all affected individuals. Se-
quence analysis of GK1 identified a nucleotide substi-
tution in exon 1 of the gene, resulting in the replacement
of the conserved proline residue at amino acid position
28 with threonine. The role of the P28T mutation in
Kalaydjieva et al.: Galactokinase Deficiency in Roma 1305
Figure 2 Marker haplotypes in the 17q24 region of disease chromosomes from Gypsy families with galactokinase deficiency. Radiation-
hybrid mapping (high-resolution TNG panel) placed the GK1 gene in very close proximity to D17S1839.
causing the disease is supported by the following ar-
guments (Cotton and Scriver 1998):
(1) The analysis of the entire coding region of GK1,
the flanking intronic sequences, and the 5′ UTR in af-
fected individuals and controls has revealed a single
change in the sequence of the patients’ DNA—namely,
the CrA transversion at nucleotide position 563 of the
gene (accession number L76927).
(2) Family analysis revealed 100% cosegregation with
the disease phenotype. All affected individuals were
found to be homozygous for the P28T mutation. P28T
also occurred in the heterozygous state among unaf-
fected siblings and followed the predictions of carrier
state, on the basis of the study of 17q24 polymorphic
haplotypes.
(3) The mutation was not detected among 128 Bul-
garian control chromosomes.
(4) The screening of 130 individuals originating from
the Gypsy groups to which the affected families belong
revealed a carrier rate of ∼5%, which is in good agree-
ment with the number of affected births detected by the
mass newborn screening (see below).
(5) The nature of the amino acid substitution, thre-
onine for proline, suggests that changes in the structure
and catalytic properties of the protein are likely to occur.
A proline residue at this position of the galactokinase
protein is conserved in evolution from Escherichia coli
(Debouck et al. 1985), to mice (Mm Unigene EST da-
tabase, AA255078) and humans. The mutation site is
in close proximity upstream to the so-called “galacto-
kinase signature sequence.” It is also located very close
to one of the two mutations described in the GK1 gene
so far, a methionine-for-valine substitution at position
32 (Stambolian et al. 1995). Computer models of protein
conformation show that V32M and P28T cause similar
changes in the secondary structure of the protein domain
immediately preceding the galactokinase signature. The
role of the galactokinase signature domain and of the
surrounding structures remains unknown; however, the
fact that two of the three known mutations in GK1 are
located within this region points to its functional sig-
nificance.
The Romani population of Bulgaria—800,000 people
in all—is a complex mosaic of a large number of en-
dogamous groups. The families with galactokinase de-
ficiency originate from three socially distinct but genet-
ically related groups that, before migrating to Bulgaria
during the last 100 years, were confined to slavery in
the Wallachian Principalities, in the northern part of the
Balkans. These groups, generally referred to as Vlax
Roma, are believed to account for as much as 40%–50%
of the Romani population of Bulgaria (Marushiakova
and Popov 1997). Our preliminary estimates, on the
basis of the analysis of 130 unrelated individuals from
these groups, suggest a carrier rate of 4%–5% and an
expected incidence of affected births of ∼1:1,600 to ∼1:
2,500 in the high-risk population. Assuming that ∼10%
of the newborns in Bulgaria are of Romani origin and
that 40%–50% of these belong to the Vlax groupswhere
P28T is common would mean that, of the total of
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Figure 3 Secondary-structure prediction for the wild-type galactokinase protein and the V32M and P28T mutants, using the PHDsec
algorithm. A selection of the first 60 amino acids is shown. xtended sheet (beta sheet); elix; oop. The prediction is meaningfulE = e H = h L = l
for all residues with an expected average correlation 1.69.
726,678 newborns screened for galactosemia, 30,000–
40,000 belong to the high-risk groups. Based on the
aforementioned carrier rate, one would predict between
12 and 25 affected births, which is in agreement with
the actual number of 14 detected children with galac-
tokinase deficiency. The Vlax Roma gave rise to the great
Gypsy diaspora in the second half of the 19th century,
after the abolition of slavery in Romania, and, currently,
they account for a large proportion of the Romani mi-
nority in most countries. Thus, P28T may be an im-
portant cause of childhood blindness in the Romaworld-
wide and should be borne in mind in the diagnostic
testing of any child with early development of cataracts.
Early investigations of the kinetic properties of rat-
liver galactokinase (Cuatrecasas and Segal 1965) have
shown that activity is high after birth and gradually de-
clines with age and that the newborn and adult forms
differ in terms of Michaelis constant, maximum velocity,
and inhibition by galactose and galactose-1-phosphate.
In human red blood cells, galactokinase activity is higher
in small infants than in older children and adults (Sitz-
mann et al. 1973; also see table 2) and age differences
in the kinetic properties of the enzyme have also been
demonstrated (Mathai and Beutler 1967). The existence
of two forms of galactokinase may help to explain why
an adult female in our study (individual 4-5; see fig. 1),
who has a history of juvenile cataracts and who is ho-
mozygous for P28T, had intermediate galactokinase ac-
tivity (0.23 mmol/hr/ml RBC). Perhaps related to the
same issue is the discrepancy between the frequency of
affected births observed in newborn screening programs
(table 1) and that predicted on the basis of erythrocyte
galactokinase activity in adult controls. Two studies
(Gitzelmann 1967; Mayes and Guthrie 1968) have
found enzyme activity in the heterozygote range in 1:
50–1:100 individuals. The predicted frequency of ho-
mozygotes, 1:10,000–1:40,000, is thus 50–100 times
higher than that actually observed.
These observations may be due to age-related differ-
ences in the expression of the GK1-encoded protein, in
terms of regulation and levels of expression, alternative
splicing, or differences in posttranslationalmodification.
They may also point to a possible sequential expression
of two forms of galactokinase encoded by different
genes. Whatever the mechanism of generating a second
(adult) form of galactokinase, its existence would have
important implications for the duration of dietary treat-
ment in patients detected by newborn screening and,
possibly, for understanding the genetic mechanisms of
susceptibility to presenile cataracts.
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